Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals

详细信息    查看全文

• 作者：Alison R Meloni (1)
  Mary Beth DeYoung (1)
  Jenny Han (1)
  Jennie H Best (1)
  Michael Grimm (1)
  
• 关键词：Number needed to treat ; Absolute benefit ; Exenatide ; Type 2 diabetes ; Diabetes mellitus ; ADA treatment guidelines ; GLP ; 1
• 刊名：Cardiovascular Diabetology
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：12
• 期：1
• 全文大小：246KB
• 参考文献：1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. / BMJ 2000,321(7258):405-12. CrossRef
  2. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B: The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. / BMJ 2010, 340:b4909. CrossRef
  3. Pedersen O, Gaede P: Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. / Metabolism 2003,52(8 Suppl 1):19-3. CrossRef
  4. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. / N Engl J Med 2003,348(5):383-93. CrossRef
  5. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. / N Engl J Med 2008,358(24):2560-572. CrossRef
  6. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. / Lancet 2010,376(9739):419-30. CrossRef
  7. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). / Lancet 1998,352(9131):854-65. CrossRef
  8. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). / Lancet 1998,352(9131):837-53. CrossRef
  9. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. / N Engl J Med 1993,329(14):977-86. CrossRef
  10. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. / Diabetes Res Clin Pract 1995,28(2):103-17. CrossRef
  11. American Diabetes Association: Standards of medical care in diabetes--2012. / Diabetes Care 2012,35(Suppl 1):S11-S63.
  12. Buse J, Henry R, Han J, Kim DD, Fineman M, Baron A: Effect of exenatide (exendin-4) on glycemic control and safety over 30?weeks in sulfonylurea-treated patients with type 2 diabetes. / Diabetes 2004,53(suppl 2):A82.
  13. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME: Metabolic effects of two years of exenatide treatment on diabetes, obesity and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. / Clin Ther 2007,29(1):139-53. CrossRef
  14. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30?weeks in metformin-treated patients with type 2 diabetes. / Diabetes Care 2005,28(5):1092-100. CrossRef
  15. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30?weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. / Diabetes Care 2005,28(5):1083-091. CrossRef
  16. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3?years. / Curr Med Res Opin 2008,24(1):275-86.
  17. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L: Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. / Cardiovasc Diabetol 2011, 10:22. CrossRef
  18. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA: Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. / Diabetes Care 2011,34(1):90-5. CrossRef
  19. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P: Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. / Diabetes Technol Ther 2011,13(11):1145-154. CrossRef
  20. Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L: DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. / J Clin Endocrinol Metab 2011,96(5):1301-310. CrossRef
  21. Buse JB, Nauck M, Forst T, Sheu WHH, Hoogwerf BJ, Shenouda SK, Heilmann CR, Boardman MK, Fineman M, Porter L: Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. / Lancet 2013,381(9861):117-24. CrossRef
  22. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. / Lancet 2008,372(9645):1240-250. CrossRef
  23. Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE: Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. / Lancet 2010,376(9739):431-39. CrossRef
  24. Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M: Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. / Lancet 2010,375(9733):2234-243. CrossRef
  25. Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, Gonzalez JG, Chan M, Wolka AM, Boardman MK: Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. / Diabetes Care 2012,35(2):252-58. CrossRef
  26. Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. / N Engl J Med 1988,318(26):1728-733. CrossRef
  27. Altman DG: Confidence intervals for the number needed to treat. / BMJ 1998,317(7168):1309-312. CrossRef
  28. Kassai B, Gueyffier F, Boissel JP, Boutitie F, Cucherat M: Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? / J Clin Epidemiol 2003,56(10):977-82. CrossRef
  29. World Medical Association: Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects. / JAMA 1997,277(11):925-26. CrossRef
  30. Jani AB, Kao J, Hellman S: Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis. / Cancer 2003,98(11):2351-361. CrossRef
  31. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH: Patient perspectives on once-weekly medications for diabetes. / Diabetes Obes Metab 2011,13(2):144-49. CrossRef
  32. Meloni AR, DeYoung MB, Lowe C, Parkes DG: GLP-1 receptor activated insulin secretion from pancreatic βeta-cells: mechanism and glucose-dependence. / Diabetes Obes Metab 2013,15(1):15-7. CrossRef
  33. Monnier L, Colette C: Target for glycemic control: concentrating on glucose. / Diabetes Care 2009,32(Suppl 2):S199-S204. CrossRef
  34. Wintle ME, Meloni AR, DeYoung MB, Li Y, Han J, Malloy J: Effects of exenatide once weekly on glycaemic goals and selected cardiovascular risk factors in patients with T2DM: a retrospective analysis of pooled clinical trial data. / Diabetologia 2011,54(Suppl. 1):S314-S315.
  35. Zinman B, Schmidt WE, Moses A, Lund N, Gough S: Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. / Diabetes Obes Metab 2012,14(1):77-2. CrossRef
  36. Cordell WH: Number needed to treat (NNT). / Ann Emerg Med 1999,33(4):433-36. CrossRef
  37. Ong KL, Cheung BM, Wong LY, Wat NM, Tan KC, Lam KS: Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-004. / Ann Epidemiol 2008,18(3):222-29. CrossRef
  38. Cook RJ, Sackett DL: The number needed to treat: a clinically useful measure of treatment effect. / BMJ 1995,310(6977):452-54. CrossRef
  39. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W: Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. / Stroke 2004,35(2):528-32. CrossRef
  40. Castelli WP: Epidemiology of triglycerides: a view from Framingham. / Am J Cardiol 1992,70(19):3H-9H. CrossRef
  41. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ: Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. / Cardiovasc Diabetol 2012, 11:64. CrossRef
  42. Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R: Treatment with exenatide once weekly or twice daily for 30?weeks is associated with changes in several cardiovascular risk markers. / Vasc Health Risk Manag 2012, 8:621-29.
  43. Finer N, Lindegaard M, Claudius B, Astrup A: Additional measures to evaluate the effect of liraglutide 3.0 mg on weight loss in obese adults without diabetes: a randomized placebo-controlled trial. / Obes Facts 2012,5(suppl. 1):46.
  44. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. / N Engl J Med 2008,359(15):1577-589. CrossRef
  45. Klonoff DC: United Kingdom prospective diabetes study follow-up studies establish a legacy effect of therapy for hyperglycemia but not hypertension. / J Diabetes Sci Technol 2008,2(6):922-24.
  46. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. / N Engl J Med 2005,353(25):2643-653. CrossRef
  
• 作者单位：Alison R Meloni (1)
  Mary Beth DeYoung (1)
  Jenny Han (1)
  Jennie H Best (1)
  Michael Grimm (1)
  
  1. Amylin Pharmaceuticals, LLC, 9360 Towne Centre Drive, San Diego, CA, 92121, USA
  

文摘

Background Diabetes is associated with a higher risk for adverse cardiovascular outcomes. To improve the health outcomes of patients with type 2 diabetes (T2DM), the American Diabetes Association (ADA) recommended target goals for the improvement of glycemic control and the reduction of cardiovascular risk factors associated with the disease. This retrospective analysis calculated the absolute benefit increase (ABI) of using exenatide once weekly (QW), a glucagon-like peptide-1 (GLP-1) receptor agonist, vs an oral glucose-lowering medication or insulin glargine to achieve ADA-recommended goals. The number needed to treat (NNT) to achieve these goals was also calculated and provides a useful clinical metric for comparing potential therapies from different drug classes. Methods Patient data from three double-blind or open label, 26-week, randomized, controlled trials were retrospectively analyzed separately. ABI and NNT were calculated by comparing the percentage of patients treated with exenatide QW (N = 641) vs metformin (N = 246), sitagliptin (N = 329), pioglitazone (N = 328), or insulin glargine (N = 223), who achieved a single glycemic, weight, blood pressure, or lipid goal or a composite of these recommended goals, during the DURATION-2, -3, and -4 clinical trials. Results Significant ABIs favoring exenatide QW over all four glucose-lowering medications were observed for at least one HbA1c glycemic goal. NNTs of 4 and 5 were calculated when exenatide QW was compared to sitagliptin for attaining HbA1c goals of <7.0% and ?.5%, respectively. Additionally, significantly more patients using exenatide QW compared to sitagliptin, pioglitazone, or insulin glargine attained the composite goal of HbA1c <7% or ?.5%, without weight gain or hypoglycemia. Exenatide QW was also favored over sitagliptin and insulin glargine for the achievement of the composite goals of HbA1c <7% (or ?.5%), systolic blood pressure <130?mm Hg, and low-density lipoprotein <2.59?mmol/L. For most goals, exenatide QW and metformin had similar effects in treatment na?ve patients. Conclusions This analysis assessed the between-therapy differences in achieving therapeutic goals with therapies commonly used for glycemic control in patients with T2DM. In clinical trials, exenatide QW assisted more patients in reaching the majority of ADA-recommended therapeutic goals than treatment with sitagliptin, pioglitazone, or insulin glargine. Trial registration NCT00637273, NCT00641056, NCT00676338